S-8 EX-FILING FEES 0002011674 Fees to be Paid N/A 0002011674 1 2025-12-29 2025-12-29 0002011674 2025-12-29 2025-12-29 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-8

YD Bio Limited

Table 1: Newly Registered Securities

                                       
Security Type   Security Class Title   Notes   Fee Calculation
Rule
  Amount Registered   Proposed Maximum Offering
Price Per Unit
  Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee
                                       
Equity   Ordinary shares, par value $0.0001 per share   (1)   Other   10,547,974   $ 12.03   $ 126,892,127.22   0.0001381   $ 17,523.80
                                       
Total Offering Amounts:   $ 126,892,127.22         17,523.80
Total Fee Offsets:               0.00
Net Fee Due:             $ 17,523.80

 

__________________________________________
Offering Note(s)

(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement on Form S-8 (the “Registration Statement”) to which this exhibit relates shall also cover any additional shares of the ordinary shares of YD Bio Limited (the “Company,” and such shares, “Company Ordinary Shares”) that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction that results in an increase in the number of outstanding shares of Company Ordinary Shares.

Fee calculated in accordance with Rules 457(c) and 457(h) under the Securities Act.

Represents shares of Company Ordinary Shares reserved for future issuance under the YD Bio Limited Equity Incentive Plan.

Estimated solely for the purpose of calculating the registration fee required by Section 6(b) of the Securities Act and calculated in accordance with Rules 457(c) and 457(h) promulgated thereunder. The aggregate offering price is the average of the high and low prices of shares of Company Ordinary Shares as reported on the Nasdaq Global Market on December 30, 2025.